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Abstract
Background: Clock genes and their protein products regulate circadian rhythms in mammals but have also been implicated
in various physiological processes, including bone formation. Osteoblasts build new mineralized bone whereas osteoclasts
degrade it thereby balancing bone formation. To evaluate the contribution of clock components in this process, we
investigated mice mutant in clock genes for a bone volume phenotype.
Methodology/Principal Findings: We found that Per2
Brdm1 mutant mice as well as mice lacking Cry2
2/2 displayed
significantly increased bone volume at 12 weeks of age, when bone turnover is high. Per2
Brdm1 mutant mice showed
alterations in parameters specific for osteoblasts whereas mice lacking Cry2
2/2 displayed changes in osteoclast specific
parameters. Interestingly, inactivation of both Per2 and Cry2 genes leads to normal bone volume as observed in wild type
animals. Importantly, osteoclast parameters affected due to the lack of Cry2, remained at the level seen in the Cry2
2/2
mutants despite the simultaneous inactivation of Per2.
Conclusions/Significance: This indicates that Cry2 and Per2 affect distinct pathways in the regulation of bone volume with
Cry2 influencing mostly the osteoclastic cellular component of bone and Per2 acting on osteoblast parameters.
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Introduction
Many biochemical, physiological, and behavioral processes
display daily rhythms generated by an internal timekeeping
mechanism called the circadian clock. The core oscillator driving
this clock is located in the ventral part of the hypothalamus, the
suprachiasmatic nuclei (SCN). At the molecular level, this
oscillator is thought to be composed of interlocking auto regulatory
feedback loops, the transcription/translation feedback loop
(TTFL) involving a set of clock genes [1], although other models
of how the clock works are increasingly discussed [2,3]. Among the
components driving the mammalian circadian clock are the Period
1 and 2 (Per1 and Per2) and Cryptochrome 1 and 2 (Cry1 and Cry2)
genes. A mutation in the mouse Per2 gene (mPer2) gene causes a
gradual loss of circadian rhythmicity in mice kept in constant
darkness (DD; [4] whereas the silencing of mCry2 leads to
immediate arrhythmicity in locomotion behavior [5]. CRY
proteins are part of the negative limb in the transcriptional/
translational feedback loop, whereas PER2 is thought to act
positively on Bmal1 expression [6,7]. Many findings implicated a
regulatory effect of CRY proteins on PER2 which was shown in
crossed double mutant mice for the Cry2 deletion being able to
compensate at least some of the Per2-related circadian clock
defects in Per2
Brdm1/Cry2
2/2 double mutants [8]. The proposed
functional antagonism of Per2 and Cry2 does not suggest a direct
effect of these proteins on each other but that separate sets of genes
and functions are affected when Per2 or Cry2 are deleted. Similar
effects have been seen before on circadian locomotor behaviour
and light-induced phase shift parameters [8].
Studies on the circadian variation of large portions of the
genome have been done in bone marrow derived mesenchymal
cells and osteoblasts [9–11] leading to the proposal that clock
genes may be involved in complex processes like bone formation
[12].
Beside its fundamental role in circadian physiology Per2 is
involved in regulation of the cell cycle [13], vascular endothelial
function [14], addiction behavior [15], food anticipation [16],
mood regulation [17], muscle strength [18], LPS-induced
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[20]. It appears that expression of Per genes in osteoblasts
negatively regulates osteoblast proliferation thereby modulating
leptin-regulated bone formation [20]. Since expression of most
clock genes oscillates in bone we investigated bone volume in mice
mutant in clock genes. In particular we were interested in the
impact of the Per2 and Cry2 genes on bone parameters in single
and double mutant female mice and provide genetic evidence for a
role of Cry2 in osteoclast physiology.
Results
Bone volume is increased in 3, 12 and 48 week old
Per2
Brdm1 mice but normal at 24 weeks
To determine the optimal age to investigate clock gene
mediated bone phenotypes we tested bone volume at various ages
in Per2
Brdm1 mice and compared them with wild type littermates.
We found that Per2
Brdm1 animals show an age-dependent bone
volume phenotype in both lumbar vertebrae and tibiae (Figure 1).
At 3, 12 and 48 weeks of age bone density was increased in
vertebral spine, but was, as shown before, statistically indistin-
guishable from wild type at 24 weeks of age ([12]; Figure 1B). Only
the 12 week old females had significantly higher tibial bone
volume (Figure 1D).
In this study we chose 12 week old mice to minimize influence
of the bone deteriorating processes occurring with ageing due to
reduced oestrogen levels. At this age we also observed the largest
difference between wild type and Per2
Brdm1 animals (Figure 1) with
a mean mineralized area in lumbar vertebrae (bone volume
divided by total volume = BV/TV) of 10.961.9% for wild type
and 18.562.8% for Per2
Brdm1 mice (p#0.001; mean6SD). The
increased volume in Per2
Brdm1 mice involved both cortical and
spongiosal structures and was not only present in female, but also
in male animals (Figure S3). These findings indicate that Per2
deficiency leads to overall increased bone volume with age-
dependency in female mice.
Bone formation rate is increased in Per2
Brdm1 mice
To determine the origin of the increased bone mineralization in
Per2
Brdm1 mice, we next investigated various indicators for
osteoblastic or osteoclastic involvement in the constitution of the
observed bone phenotypes. We found that the number of
osteoblasts and osteoclasts per bone perimeter was not different
between wild type and Per2
Brdm1 mutant animals (Figure 2A and B,
respectively). In line with this finding was the observation that the
serum concentrations of the circulating osteoclast activity marker
TRAP5b [21,22] as well as the osteoblast activity marker
osteocalcin did not differ between wild type and Per2
Brdm1 animals
(Figure 2C and D, respectively). Neither conventional curve nor
cosinor analysis showed any statistically significant difference in
the mesor, acrophase or amplitude of the serum osteocalcin
Figure 1. Mineralized bone area in vertebrate spine and tibia and age-dependent differences in bone mineral density in Per2
Brdm1
mutant mice. (A) Representative examples of photomicrographs of the mineralized bone area in lumbar vertebrae of 3, 12, 24 and 48 week old
Per2
Brdm1 mutant mice and their wild type littermates. Black areas represent calcified extracellular matrix, as visualized by Von Kossa staining. (B)
Quantitative analysis of BV/TV (bone volume as a ratio of tissue volume) values of lumbar vertebrae for the different age groups. Shown are the
means (in percent) 6SD (*=p,0.05, **=p,0.01, ***=p,0.001, ANOVA with Bonferroni post-test). Note that the significant differences at 3, 12 and
48 weeks of age is absent in the 24 week age group. (C) Representative examples of photomicrographs of the mineralized bone area in tibiae of 3, 12,
24 and 48 week old female wild type and Per2
Brdm1 mutant mice. Black areas represent calcified extracellular matrix, as visualized by Von Kossa
staining. (D) Quantitative analysis of BV/TV values of tibiae for the different age groups. Shown are the means6SD (*=p,0.05, **=p,0.01,
***=p,0.001, ANOVA with Bonferroni post-test).
doi:10.1371/journal.pone.0011527.g001
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which is mainly influenced by osteoblasts, was significantly higher
in Per2
Brdm1 mice as compared to wild type littermates (p#0.01;
Figure 2E). These findings suggest that other factors regulating
osteoblast activity may be altered in Per2
Brdm1 mutant mice. In this
context we observed that osteoblasts from Per2
Brdm1 mutant mice
exerted a significantly higher ability to form bone nodules after 14
days in culture (Figure S5).
Osteoblast markers are not changed in Cry2
2/2 mice
Similar to Per2
Brdm1, also Cry2
2/2 mice displayed a mean
vertebral spine density (BV/TV) of 21.661.5% (mean6SD) in
comparison to wild type (10.961.9%; Figure 3A). The tibiae of
Cry2
2/2 mice displayed also a significantly higher bone volume
(Figure S4). In order to find a cellular basis of the Cry2 defect, we
investigated the same parameters as described above for the Per2-
deficient animals. We found that both the number of osteoblasts
and the number of osteoclasts per bone perimeter was not different
between wild type and Cry2
2/2 mutant animals (Figure 3A and B,
respectively). Also, bone formation rate and the levels of the
osteoblast activity marker osteocalcin in serum did not differ
between wild type and Cry2
2/2 (ANOVA with Bonferroni post-
test; Figure 3C, D, respectively). However, in contrast to Per2
Brdm1
mutant mice, the serum levels of the circulating osteoclast activity
marker TRAP5b [21,22] were significantly lowered at any time
point in Cry2
2/2 animals as compared to wild type mice
Figure 2. Osteoblast, osteoclast and serum parameters in Per2
Brdm1 mutant mice. (A) Osteoblast number per bone perimeter (Ob.N./B.pm)
in 12 week old wild type and Per2
Brdm1 mutant female mice. The number of osteoblasts per bone perimeter is not significantly different between wild
type and Per2
Brdm1 mice. (B) Osteoclast number per bone perimeter (Oc.N./B.pm) in 12 week old wild type and Per2
Brdm1 mutant female mice. The
number of osteoclasts per bone perimeter is not significantly different between wild type and Per2
Brdm1 mice. (C) Serum levels of the circulating
osteoclast marker TRAP5b in female wild type and Per2
Brdm1 mice. (D) Serum levels of the osteoblast activity marker osteocalcin in female wild type
and Per2
Brdm1 mice. (E) Bone formation rate (BFR) (mm
3/mm
2/day)) in female wild type and Per2
Brdm1 mice. Shown are the means6SD (panel A, B, E) or
SEM (panel C and D) (*=p,0.05, **=p,0.01, ***=p,0.001, ANOVA with Bonferroni post-test).
doi:10.1371/journal.pone.0011527.g002
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indicates reduced osteoclast activity and hence lower bone
resorption in Cry2
2/2 mice and correlates with our observation
that these animals show higher bone volume. These findings
strongly suggest that the bone phenotype of the Cry2-deficient
female animals is based on lowered osteoclast activity and hence is
mechanistically different from the bone phenotype observed in
Per2
Brdm1 mutant animals.
Phenotypic compensation in Per2
Brdm1/Cry2
2/2 mice
The two apparently mechanistically different bone phenotypes
in Per2-o rCry2-deficient female mice and the previously described
non-allelic compensation of the different chrono-phenotypes that
these animals display [8] lead us to investigate bone parameters in
the Per2
Brdm1/Cry2
2/2 double mutant mice.
In these animals bone volume in vertebrae (BV/
TV=12.462.4%) was indistinguishable from wild type (BV/
TV=10.961.9%; Figure 4A). Also tibial bone volume was not
different between wildtype and Per2
Brdm1/Cry2
2/2 double mutant
mice (Figure S4). The number of osteoblasts per bone perimeter
was significantly lower in double mutant mice (p,0.05; ANOVA
with Bonferroni post-test; Figure 4B). Interestingly, the osteoclast
number per bone perimeter was normal (Figure 4C) and
comparable to Cry2
2/2 mice (Figure 3B). These findings correlate
well with the reduced bone formation rate (BFR) observed in
double mutant mice, as compared to wild type controls (p,0.01;
Figure 3. Osteoblast, osteoclast and serum parameters in Cry2
2/2 mice. (A) Osteoblast number per bone perimeter (Ob.N./B.pm) in 12 week
old wild type and Cry2
2/2 mutant mice. (B) Osteoclast number per bone perimeter (Oc.N./B.pm) in 12 week old female wild type and Cry2
2/2 mutant
mice (C) Bone formation rate (BFR) (mm
3/mm
2/day) in female Cry2
2/2 mutant mice and wild type controls. (D) Serum levels of the osteoblast activity
marker osteocalcin in female wild type or Cry2
2/2 mutant mice. (E) Serum levels of the circulating osteoclast marker TRAP5b in 12 week old wild type
and Cry2
2/2 mutant mice. Shown are the means6SD (panel A–C) or SEM (panel D,E) (*=p,0.05, **=p,0.01, ***=p,0.001, ANOVA with Bonferroni
post-test).
doi:10.1371/journal.pone.0011527.g003
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PLoS ONE | www.plosone.org 4 July 2010 | Volume 5 | Issue 7 | e11527Figure 4. Osteoblast, osteoclast and serum parameters in Per2Brdm1/Cry22/2 double mutant mice. A) Representative images of lumbar
vertebral spine from 12 week old female Per2Brdm, Cry22/2, and Per2Brdm1/Cry22/2 mice. B) Osteoblast number per bone perimeter (Ob.N./
B.pm) in 12 week old female wild type and Per2Brdm1/Cry22/2 double mutant mice. C) Osteoclast number per bone perimeter (Oc.N./B.pm) in 12
week old wild type and Per2Brdm1/Cry22/2 double mutant mice. D) Bone formation rate (BFR) (mm3/mm2/day) in 12 week old female wild type and
Per2Brdm1/Cry22/2 double mutant mice. E) Serum levels of the osteoblast activity marker osteocalcin in wild type and Per2Brdm1/Cry22/2 double
mutant animals. F) Serum levels of the circulating osteoclast marker TRAP5b in wild type and Per2Brdm1/Cry22/2 double mutant mice. G) Wheel
running activity (total number of wheel rotations evaluated over 5 days under 12:12 LD) of male wild type, Per2Brdm1, Cry22/2 and Per2Brdm1/
Cry22/2 mice. Shown are the means + SD (*=p,0.05, **=p,0.01, ANOVA with Bonferroni post-test).
doi:10.1371/journal.pone.0011527.g004
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indicate normal activity of these osteoblasts (Figure 4E). However,
similar to the Cry2
2/2 mutants, the circulating osteoclast activity
marker TRAP5b was significantly lowered in plasma of double
mutant mice at all times (Figure 4F), suggesting lowered osteoclast-
dependent bone degradation. It appears that Per2 affects the
osteoblastic parameter bone formation (anabolic process), whereas
Cry2 influences osteoclast activity (catabolic process). Hence, the
two clock genes affect bone mineral density in an opposite manner.
Mechanical load is normal in Per2
Brdm1, Cry2
2/2 and
Per2
Brdm1/Cry2
2/2 mice
An important parameter influencing bone strength and density
is mechanical load. Under constant conditions wheel running
activity of all four investigated genotypes was equal (Figure 4F).
Moreover, under light/dark conditions Per2
Brdm1 and Cry2
2/2
mice were as active as wild type and double mutant animals.
Another possible influence may be different body weight between
the genotypes. Although Per2
Brdm1 are slightly heavier than wild
type littermates in the first few months of age, they are not
different at older age [23,24]. The body weight of the Cry2
2/2
mice did not differ from wildtype. Since Per2
Brdm1/Cry2
2/2 mice
are also slightly heavier than wild type in the same time period as
the Per2
Brdm1 mutants it is unlikely that weight is the reason for the
observed differences in bone density between genotypes.
Discussion
Per2
Brdm1/Cry2
2/2 double mutants display wild type bone
volume suggesting that Cry2 can act as a non-allelic suppressor
of Per2 in bone formation. However, Per2
Brdm1 animals display
increased bone formation and Cry2
2/2 mice decreased bone
resorption. Therefore, we expected to find a ‘‘super-dense-bone’’
phenotype in the double mutant animals, which is in contrast to
what we observed. How can increased bone formation and
reduced bone resorption combine to a seemingly normal bone?
The answer could lie in the central regulation of bone remodelling
that is determined by both afferent and efferent signalling through
the hypothalamus.
It has been described that the leptin signal originating in
peripheral adipocytes is processed in the hypothalamus from
where mediators including neuropeptide Y (NPY) and neurome-
din U (NMU) affect osteoblast and osteoclast function [25]. This
hypothesis is bolstered by the observation that NMU affects bone
remodelling [26]. We observed higher NMU-precursor levels in
Per2
Brdm1 mutant mice in comparison to wildtype littermates at
ZT04 (four hours after lights on; Figure S6). Alterations in NMU
levels support the view that hypothalamic mechanisms are
responsible for the rescue of the bone phenotype in Per2
Brdm1/
Cry2
2/2 double mutant mice. For NMU both systemic [25,26]
and direct cellular [27] influence on osteoblast parameters has
been shown making NMU a potential candidate for the mediation
of Per2 effects on bone mineral density. However, whether
neuromedin U affects bone formation on the local cellular, the
systemic hypothalamic, or both levels, is unclear [25–27]. We also
observed elevated parathyroid hormone (PTH) levels in the serum
of Per2
Brdm1 mutant mice at ZT 04 (Figure S7). Finally, osteoblasts
cultivated from Per2-luciferase reporter gene mice displayed
autonomous circadian oscillation without any input from the
central nervous system (Figure S2)[28]. Autonomous circadian
cycling of various mesenchymal stem cells from different sources
and osteoblasts has been described before [9,11,29,30] and has
been recently reviewed [12]. Taking all these findings together it is
highly probable that both local bone regulatory processes in the
osteoblasts and osteoclasts and the central oscillator in the SCN
contribute to bone formation and bone volume regulation.
Another interesting finding is that the Cry2
2/2 phenotype
appears to be mostly unaffected by the functional Per2-deficit of
the Per2
Brdm1 mutants. In both the single Cry2
2/2 and the double
mutant Per2
Brdm1/Cry2
2/2 animals circulating TRAP5b levels are
significantly reduced. It has been shown that Cry2 deficiency leads
to downregulation of NFkB-RelA [31]. NFkB -RelA promotes
osteoclast differentiation by blocking a RANKL- induced JNK
pathway [32]. Therefore NFkB -RelA deficiency should lead to
lower osteoclastic activity which is in line with our observations
and might possibly explain the bone resorption phenotype of both
the Cry2
2/2 and Per2
Brdm1/Cry2
2/2 deficient mice. However, both
osteoblast number and bone formation rate are reduced in the
Per2
Brdm1/Cry2
2/2 double mutant animals, but unaffected (osteo-
blast number) and increased (bone formation rate) in the single
mutant Per2
Brdm1. Thus the Cry 2
2/2 bone phenotype persists
irrespectively of the simultaneous absence of the Per2 gene. This
parallels the finding, that there is no obligatory cross-regulation
between bone formation and bone resorption [33–35]. Whereas
Cry2 exerts its effects on the osteoclasts no matter if Per2 is present
or not, the osteoblastic effects of Per2 appear to be Cry2-
dependent, since in the absence of Cry2 both bone formation rate
and osteoblast number are significantly lowered whereas in the
presence of Cry2, the Per2
Brdm1 mutant mouse bone formation rate
was higher than in wildtype littermates. The mechanistic basis for
this observation is unclear, but the data speaks for a non-
redundancy of the Cry (Cry1 cannot compensate for the absence
of Cry2) genes at least for the bone phenotype.
The model that emerged from earlier studies highlighted a role
of clock genes (Per1 and Per2) in the leptin-dependent modulation
of osteoblast proliferation. Here we extend these findings and
report that the action of clock genes in bone remodelling is not
limited to osteoblasts, but also involves osteoclast regulation.
Taken together, our findings illustrate that molecular compo-
nents of the circadian clock mechanism play a critical role in the
anabolic and catabolic mechanisms of bone volume regulation.
These functions of the clock genes Per2 and Cry2 may not depend
on circadian regulation phenomena since the observed bone
phenotypes occur under diurnal (light dark) conditions. In
particular it appears that Per2 and Cry2 have opposite effects on
bone metabolism via unknown mechanisms regulating osteoblasts
and osteoclasts, respectively. Future studies will show whether
specific pharmaceutical targeting of Cry2 or Per2 can serve as a
new therapeutic avenue to treat bone loss conditions such as
osteoporosis.
Materials and Methods
Mice
The Per2
Brdm1, Cry2
2/2, and Per2
Brdm1/Cry2
2/2 mice and wild
type littermates (all in a hybrid 129Sv/C57BL6 genetic back-
ground) used for this study have been described previously [4,5,8].
All animal experiments were approved by the Animal Care
Facilities of the Hamburg, Frankfurt and Fribourg Universities
and performed according to the Declaration of Helsinki. Mice
were fed a standard rodent diet and housed in a regular (12 h
light/12 h dark) light/dark cycle (12/12LD). The bone phenotype
was analyzed at the ages of 3, 12, 24 and 48 weeks. Given the
absence of significant sex differences (data not shown), only data
from female mice are presented in this manuscript. To assess
dynamic histomorphometric indices, mice were given two
injections of calcein green 9 and 2 days before animals were
sacrificed. At least five mice per group were subjected to
Per2 and Cry2 Effects on Bone
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significant results. For the quantification of bone development a
total of 80 (20 per age class) female mice of the clock gene mutant
animals or wild type controls were screened by radiography.
Histomorphometry
Skeletons were fixed in 3.7% PBS-buffered formaldehyde for
18 h at 4uC. After 24-h incubation in 70% ethanol, the lumbar
vertebral bodies (L3–L5) and one tibia of each mouse were
dehydrated in ascending alcohol concentrations and embedded in
methylmethacrylate as described previously [36,37]. Sections of
5 mm were cut in the sagittal plane on a Microtec rotation
microtome (Techno-Med, Munich, Germany). These sections
were stained by the van Gieson/von Kossa procedure as described
[36]. Nonstained sections of 12 mm were used to determine the
bone formation rate (BFR in mm
3/mm
2/day).
Parameters of static and dynamic histomorphometry were
quantified on toluidine blue–stained undecalcified proximal tibia
and lumbar vertebral sections of 5 mm. Analysis of bone volume,
trabecular number, trabecular spacing, trabecular thickness, and
the determination of osteoblast and osteoclast numbers and surface
were carried out according to standardized protocols using the
Osteo-Measure histomorphometry system (Osteometrics, Atlanta,
GA,USA) [37]. Fluorochrome measurements for the determination
of bone formation rate were performed on two nonconsecutive 12-
mm sections for each animal. Statistical differences between the
groups (n$5) were assessed by ANOVA with subsequent
Bonferroni post test using p#0.05 as the criterion for significance.
Biochemical assays
Blood was taken from the same mice 4 times every 6 hours (at
Zeitgeber time 0/24, 06, 12 and 18; Zeitgeber time 0 is defined as
the start of the light period) retro-orbitally. Serum was produced
from retro-orbital blood as described before [38]. Serum
concentrations of hormones were quantified using antibody-based
detection kits (Osteocalcin, from Immutopics, Los Angeles, CA,
USA; TRAP5b from IDS, UK).
Statistical analysis
Data were analysed by GraphPad prism 3.0. Group comparison
was done by Stdents t-test, curve comparison by ANOVA with
Bonferroni post-test. Possible differences betewwn the genotypes
over the course of the day, namely mesor, amplitude and
acrophase changes in the osteocalcin and TRAP5b-levels were
analyzed by COSINOR analysis as implemented in the MathLab
software.
Supporting Information
Figure S1 Data on osteocalcin levels at different times (ZT00,
ZT06, ZT12 and ZT18) in serum of wildtype, Per2
Brdm1, Cry2
2/2,
and Per2
Brdm1/Cry2
2/2 mice were subjected to COSINOR
analysis. There was no statistical difference in the mesor,
acrophase or amplitude of the osteocalcin profiles.
Found at: doi:10.1371/journal.pone.0011527.s001 (0.12 MB
PDF)
Figure S2 Calvarial osteoblasts from newborn Period2-promot-
er-luciferase transgenic (mPer2-luc) mice were prepared as
described by Kramer et al (2008). The experiment was started
by adding fresh medium containing D-luciferin (100 mM) and
relative light emission (RLU) was recorded for 68 hours. The
cultured osteoblasts oscillate with a approximately 24 hour period.
Found at: doi:10.1371/journal.pone.0011527.s002 (0.01 MB
PDF)
Figure S3 The vertebrae of male mice were prepared as
described in Materials and Methods of the main text. The BV/
TV-value of the 12 week old male Per2
Brdm1 was significantly
higher than that of wildtype littermates (p#0.05, Student’s t-test).
Found at: doi:10.1371/journal.pone.0011527.s003 (0.00 MB
PDF)
Figure S4 The tibiae of female mice were prepared as described
in Materials and Methods of the main text. The BV/TV-value of
the 12 week old female Cry2
2/2 mice was significantly higher than
that of wildtype littermates (p#0.01, ANOVA with Bonferroni
post-test). Wildtype and Per2
Brdm1/Cry2
2/2 mice were not
statistically different.
Found at: doi:10.1371/journal.pone.0011527.s004 (0.00 MB
PDF)
Figure S5 Primary osteoblasts were obtained by sequential
collagenase digestion of calvariae from 3-day-old mice. Osteoblast
differentiation was induced at 80% confluency in a-MEM
containing 10% FBS, 50 mg/ml ascorbic acid, and 10 mM b-
glycerophosphate. Analysis of ECM mineralization was deter-
mined by Von Kossa staining as described [4] and reveals an
accelerated mineralization of Per2
Brdm1 derived primary osteoblast
cultures compared with wild-type cultures (p#0.001, Student’s t-
test).
Found at: doi:10.1371/journal.pone.0011527.s005 (0.00 MB
PDF)
Figure S6 Neuromedin U (NMU) precursor levels in plasma at
ZT04 (four hours after lights on) were determined by SDS-PAGE
and Western blotting using affinity-purified rabbit anti-mouse
NMU antiserum (1:1000; Alpha Diagnostics, San Antonio, TX,
USA). NMU precursor levels were significantly higher in plasma
from Per2
Brdm1 compared to wildtype (p#0.001, Student’s t-test).
Found at: doi:10.1371/journal.pone.0011527.s006 (0.00 MB
PDF)
Figure S7 Intact parathyroid hormone (iPTH) levels in plasma
at ZT04 (four hours after lights on) were determined by the mouse
intact PTH ELISA kit (Immutopics, San Clemente, CA, USA).
Intact PTH levels were significantly higher in plasma from
Per2
Brdm1 compared to wildtype (p#0.01, Student’s t-test).
Found at: doi:10.1371/journal.pone.0011527.s007 (0.00 MB
PDF)
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